Tisdag 3 November | 13:01:53 Europe / Stockholm
Est. tid*
2028-02-10 08:00 Bokslutskommuniké 2027
2027-10-28 08:00 Kvartalsrapport 2027-Q3
2027-08-19 08:00 Kvartalsrapport 2027-Q2
2027-05-04 N/A Årsstämma
2027-04-28 08:00 Kvartalsrapport 2027-Q1
2027-02-12 08:00 Bokslutskommuniké 2026
2026-10-28 - Kvartalsrapport 2026-Q3
2026-08-20 - Kvartalsrapport 2026-Q2
2026-05-07 - X-dag ordinarie utdelning DICOT 0.00 SEK
2026-05-06 - Årsstämma
2026-04-30 - Kvartalsrapport 2026-Q1
2026-02-18 - Bokslutskommuniké 2025
2025-10-23 - Kvartalsrapport 2025-Q3
2025-08-12 - Kvartalsrapport 2025-Q2
2025-05-07 - X-dag ordinarie utdelning DICOT 0.00 SEK
2025-05-06 - Årsstämma
2025-04-29 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-08-01 - Extra Bolagsstämma 2024
2024-05-07 - X-dag ordinarie utdelning DICOT 0.00 SEK
2024-05-06 - Årsstämma
2024-05-06 - Kvartalsrapport 2024-Q1
2024-02-26 - Bokslutskommuniké 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-24 - X-dag ordinarie utdelning DICOT 0.00 SEK
2023-05-23 - Årsstämma
2023-05-19 - Kvartalsrapport 2023-Q1
2023-02-27 - Bokslutskommuniké 2022
2023-01-09 - Extra Bolagsstämma 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning DICOT 0.00 SEK
2022-05-24 - Årsstämma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-28 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-10-06 - Extra Bolagsstämma 2021
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-26 - X-dag ordinarie utdelning DICOT 0.00 SEK
2021-05-25 - Årsstämma
2021-05-17 - Kvartalsrapport 2021-Q1
2021-02-24 - Bokslutskommuniké 2020
2020-11-23 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning DICOT 0.00 SEK
2020-05-26 - Årsstämma
2020-05-15 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-28 - Kvartalsrapport 2019-Q3
2019-08-22 - Extra Bolagsstämma 2019
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning DICOT 0.00 SEK
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Dicot Pharma utvecklar läkemedelskandidaten LIB-01 vilket förväntas bli ett potensläkemedel för att behandla erektionssvikt och tidig utlösning. Verkningstid och färre biverkningar är huvudsakliga önskade egenskaper. Dicots huvudstrategi är att under utvecklingen av LIB-01 löpande utvärdera industriella partnerskap för att ta läkemedelskandidaten fram till kommersialisering. Bolaget är baserat i Uppsala.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Nomination Committee appointed for Dicot Pharma AB

2026-11-02 15:00:00

Uppsala, Sweden, November 2, 2026. A Nomination Committee has been appointed for Dicot Pharma AB in accordance with the resolution of the Annual General Meeting. The Nomination Committee consists of Göran Beijer, Carl Leijonhufvud and Tore Robertsson.

Under the instructions for the Nomination Committee adopted by the Annual General Meeting, the members of Dicot Pharma’s Nomination Committee are to be appointed by the three largest shareholders or shareholder groups in the company in terms of voting rights that wish to appoint a member. The selection is based on the ownership structure as of 30 September 2026.

The Nomination Committee has now been appointed and consists of the following three members:

  • Göran Beijer, appointed by Bertil Lindkvist
  • Carl Leijonhufvud
  • Tore Robertsson, representing Tor Finans AB

Tore Robertsson has been appointed Chair of the Nomination Committee. He has asked Eva Sjökvist Saers, Chair of the Board, to convene the Nomination Committee. No remuneration will be paid to the members of the Nomination Committee.

The Nomination Committee’s proposals will be presented in connection with the notice of the forthcoming Annual General Meeting. The Nomination Committee is responsible for preparing and presenting proposals for the Chair of the Board, Board members and the Chair of the Annual General Meeting, as well as for the election of auditors. Its remit also includes proposals for Board remuneration, allocated between the Chair, members and any committees, as well as remuneration of the auditors.

Shareholders’ proposals should reach the Nomination Committee no later than December 18, 2026 to allow them to be considered constructively. Proposals should be submitted by email to eva.sjokvist@saers.se.

Dicot Pharma’s 2027 Annual General Meeting will be held on Tuesday, May 4, 2027 at 5:00 p.m. in Uppsala.

For further information, please contact:
Eva Sjökvist Saers, Chair of the Board
Telephone: +46 70 550 7371
Email: eva.sjokvist@saers.se